Apigenin for sleep

Editorial draft: machine-assisted translation of the cited source article. The text has been read in full and copyedited. Independent clinical review and source verification are still pending. Statements and amounts taken from the source article are not individual treatment recommendations.

What apigenin has to do with chamomile and sleep

Apigenin is a flavone, a subclass of flavonoids. It is especially concentrated in German chamomile (Matricaria chamomilla) but also occurs in parsley, celery and other plants. Pharmacologically, it acts as a partial agonist at the benzodiazepine binding site of the GABA-A receptor (the brain receptor that benzodiazepines bind to). It is sold as an isolated dietary supplement, even though most clinical data in humans come from chamomile preparations rather than isolated apigenin capsules. Source

Flavones differ from flavonols (such as quercetin) and flavanones (such as hesperidin) in their hydroxylation pattern and in whether the C2-C3 bond is saturated. This structural difference matters because GABA-A binding affinity depends on the molecule’s shape. Closely related flavones (including vitexin, an apigenin glycoside) show some of the same GABAergic activity. This is read as a hint that the compound class has a sedative effect. Source

The flavone backbone

Apigenin’s chemical name is 4’,5,7-trihydroxyflavone. It carries three hydroxyl groups at positions 4’, 5 and 7. The 5,7-dihydroxylation pattern supports its affinity for the benzodiazepine binding site. In chamomile, apigenin is present mainly as apigenin-7-glucoside, the plant’s most important sedative flavonoid. Beta-glucosidases in the gut cleave off this sugar and release free apigenin for absorption. Source

Oral bioavailability is poor across the board. Free apigenin is extensively transformed in the gut wall and liver, mainly by glucuronidation and sulfation, before it reaches the systemic circulation. This is where research on L-lysine conjugates comes in: L-lysine conjugation improves apigenin’s passage across the blood-brain barrier, which would be necessary for a stronger effect on the CNS. How apigenin’s structure shapes its effects in the central nervous system (CNS) is still being studied. Most of the work on this is preclinical. Source Source

From chamomile tea to dietary supplement

Chamomile has been used for centuries in the traditional medicine of Europe and the Mediterranean as a calming remedy and anxiolytic. Surveys of medicinal plant use show that chamomile is among the most commonly used traditional remedies for sleep and nervous complaints. This long history of use concerns chamomile preparations (teas, tinctures and standardized extracts), not isolated apigenin. Source

The wellness market’s interest in isolated apigenin took off between 2021 and 2022, mostly after a widely followed sleep protocol recommendation made it popular. The distinction matters: chamomile’s safety and efficacy record in clinical settings spans decades and several populations. For isolated apigenin supplements, there is much less experience and far fewer data. Results from clinical trials of oral chamomile consistently show positive effects on sleep and anxiety. These results are what drive the interest in apigenin. Marketing, however, has to make clear that they come from chamomile studies. Source Source

How apigenin acts at the GABA-A receptor

The main proposed mechanism of action for apigenin is partial agonism at the benzodiazepine binding site of the GABA-A receptor. This is the same site that prescription benzodiazepines target, but apigenin binds with much weaker affinity. A secondary mechanism, CD38 inhibition and its downstream effects on cellular NAD+ metabolism, has attracted a lot of interest in the longevity market. For this second mechanism, only preclinical data exist.

How apigenin binds

GABA-A receptors are ligand-gated chloride channels. When GABA binds, the channel opens and chloride flows in, which hyperpolarizes the neuron and lowers its excitability. Benzodiazepines amplify this effect by binding to an allosteric site, the benzodiazepine binding site, and increasing how often the channel opens. Apigenin binds to the same site. In animal models, apigenin modulates GABA-A receptor expression and reduces seizure susceptibility, which is consistent with partial agonist activity. Its affinity is measurable but weaker than that of medically used benzodiazepines, which is why any sedation is mild rather than anesthetic. Apigenin’s GABA-A activity has been compared with the anxiolytic mechanism of valerian, another flavonoid-rich botanical with overlapping pharmacology. Source Source

CD38 inhibition is a separate mechanism. CD38 is an NAD+ase, an enzyme that breaks down NAD+. Apigenin inhibits CD38 and raises intracellular NAD+ levels in preclinical models. Because NAD+ declines with age and is central to mitochondrial function and sirtuin activity, this mechanism is the basis for marketing apigenin as a longevity aid. CD38 is a key regulator of inflammation and a possible drug target, and inhibiting CD38 in combination with NAD+ precursors reduces neuroinflammation in animal models. Whether oral apigenin, given its poor bioavailability, meaningfully changes NAD+ levels in humans is unproven. Improving apigenin’s passage across the blood-brain barrier through L-lysine conjugation has been proposed as one route to stronger CNS and longevity effects, but this is still under investigation. Source Source Source Source

Pharmacokinetics: absorption, half-life, metabolism

The bioavailability of oral apigenin is poor because of its chemistry. In chamomile, it occurs mainly as apigenin-7-glucoside. Gut beta-glucosidases hydrolyze the glucoside to free apigenin, which is then absorbed but heavily glucuronidated and sulfated in the gut wall and liver before it reaches the systemic circulation. So the dose you swallow does not simply tell you how much free apigenin ends up in the plasma: that kind of calculation overestimates how much reaches the target tissue. In typical pharmacokinetic reports, Tmax is about 1 to 2 hours; the half-life is short, generally under 12 hours.

This matters for timing. If the goal is falling asleep, the source article derives from the Tmax of 1 to 2 hours that apigenin should be taken 1 to 2 hours before bed. The short half-life, though, means it is largely cleared by morning, which is framed as a possible advantage over longer-acting sedatives. L-lysine conjugation has been shown to improve apigenin’s passage across the blood-brain barrier. Formulations like this might be needed to achieve a stronger CNS effect after oral intake. Standard capsule formulations have not yet shown correspondingly high amounts of the compound in the CNS in human studies. Source

How well supported are the claims?

The evidence base for apigenin has to be looked at separately for each claimed effect. Most human data come from chamomile preparations, in which apigenin and apigenin-7-glucoside are the main sedative flavonoids, and not from isolated apigenin supplements. There are no completed human RCTs on possible life extension or on NAD+. The ratings below reflect this distinction throughout. Source

Evidence grades used below:

• Strong: >=2 well-designed human RCTs on a clinically meaningful endpoint, ideally with a meta-analysis showing a consistent direction of effect. Or a single very large randomized controlled trial (N>1,000) with replicable methods.

• Moderate: >=1 human RCT with a clinically meaningful endpoint OR several smaller RCTs with mixed results OR a single high-quality randomized controlled trial on a surrogate endpoint.

• Limited: only small (N<50), short (<8 weeks) or methodologically weak human studies; or only observational human data.

• Animal / preclinical only: no completed human trials. Only in vitro, animal model or phase 1 safety data.

• Anecdotal: no controlled evidence; case reports, testimonials, mechanistic plausibility or marketing claims not supported by published data.

Apigenin (via chamomile preparations) and sleep quality: moderate evidence

Two placebo-controlled RCTs support this claim. A standardized chamomile extract produced small improvements in sleep quality in adults with chronic primary insomnia. Oral chamomile improved sleep quality in older participants in a separate RCT, with the strongest effects documented in older adults. The strength of this evidence is limited: most studies are small (N under 100), they tested chamomile extract rather than isolated apigenin, and the effect sizes are modest. A systematic review of clinical trials of oral chamomile confirms a consistent direction of effect for sleep and anxiety but notes heterogeneity between studies. Data on isolated apigenin supplements remain thinner than the chamomile literature might suggest. Source Source Source

Apigenin/chamomile for anxiety relief: moderate evidence

A systematic review of clinical trials of oral chamomile for anxiety found consistent anxiolytic signals across several studies, mainly in mild to moderate generalized anxiety. The benzodiazepine binding site mechanism makes the effect pharmacologically plausible: apigenin’s GABAergic activity at the receptor level offers a plausible explanation for an anxiety-relieving effect. The limits: outcome measures vary from study to study, most studies use chamomile preparations rather than isolated apigenin, and these data do not justify using apigenin as a substitute for first-line treatment of anxiety disorders. Apigenin’s activity at the GABA-A benzodiazepine binding site is well characterized mechanistically, but the effect of isolated apigenin supplements still needs to be studied specifically in humans. Source Source Source

Apigenin supports longevity through CD38 inhibition and NAD+ preservation: animal and preclinical data only

Apigenin inhibits the NAD+ase CD38 and raises intracellular NAD+ levels in preclinical models. This research is the basis for the promise of a life-extending effect. CD38 is a validated drug target in the biology of inflammation and aging, so the mechanism is scientifically coherent. What remains open is whether it carries over to humans: no human RCTs have tested isolated apigenin against a longevity endpoint, and apigenin’s poor oral bioavailability raises real questions about whether supplement doses change NAD+ levels in human tissue to any meaningful degree. Of all the marketing claims, this one has the least human evidence. Source Source

Apigenin supports metabolic health: animal and preclinical data only

In a recent preclinical study, oral apigenin prevented obesity-related muscle atrophy in middle-aged rats. That is an interesting metabolic finding, but it has not yet been reproduced in humans. Chamomile and apigenin have been studied for effects on obesity and metabolic syndrome, with plausible mechanisms involving antioxidant and anti-inflammatory pathways. Both cited papers provide preclinical data. No human RCTs have tested isolated apigenin on body composition, insulin sensitivity or other metabolic endpoints. Source Source

It has not been shown that apigenin reverses aging in humans, extends life, replaces first-line treatment for insomnia or generalized anxiety disorder, or produces clinically meaningful NAD+ changes in humans. Nor is there any FDA-approved use for treating a disease.

Isolated apigenin vs. chamomile extract

Form matters more than usual here, because oral bioavailability is poor to begin with. Most consumer products are either isolated apigenin (typically 50 mg or 100 mg capsules) or standardized chamomile extract, often standardized to a stated percentage of apigenin or apigenin-7-glucoside. Pharmacologically, then, the products are not the same.

Standardized chamomile extract contains the full mix of active compounds from Matricaria chamomilla. Besides apigenin, that includes bisabolol and chamazulene, compounds with their own anti-inflammatory and antispasmodic effects. Isolated apigenin captures a single mechanism. Neither form has been compared head to head in a human RCT for sleep or anxiety, so the question “which is better?” remains open. To judge a product, the source article points to third-party testing certification (USP, NSF International or ConsumerLab verification), a certificate of analysis (COA) documenting the standardization marker (percentage of apigenin or apigenin-7-glucoside), and labeling of possible allergens from the daisy family (Asteraceae). Chamomile belongs to the daisy family, and sensitive people should be aware of cross-reactivity with ragweed. Dry extracts of German chamomile vary considerably in apigenin content depending on the extraction method, which is why the certificate of analysis matters. Source

Regulatory status of apigenin as of May 2026

In the United States, apigenin is sold as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA). It is not FDA-approved as a drug, and the FDA has not reviewed any efficacy claims. According to the source article, no New Dietary Ingredient (NDI) notifications for isolated apigenin are known to have led to public FDA action. Chamomile, the primary natural source, has GRAS (Generally Recognized As Safe) status for use in food, but GRAS status for food use does not extend to supplement doses of isolated apigenin.

As of the last update, apigenin is not on the World Anti-Doping Agency (WADA) Prohibited List. Through May 2026, no FDA warning letters specifically targeting apigenin as a standalone ingredient were identified. As with all dietary supplements, structure/function claims on product labels are not evaluated by the FDA. If you have a chronic condition or take prescription medication, talk to a doctor before taking it.

If sleep or anxiety problems are severe, a medical evaluation should come first. The US source article lists the 988 Suicide and Crisis Lifeline (call or text 988) and the SAMHSA National Helpline (1-800-662-4357) as round-the-clock help in a mental health crisis.

Safety, side effects and drug interactions

Apigenin’s safety record is dominated by the literature on chamomile preparations, which spans decades and several clinical populations. Safety data on isolated apigenin supplements are thinner, but in scope they match what has been documented in chamomile studies. The most clinically relevant concerns are increased central nervous system depression and CYP3A4 interactions (CYP3A4 is the liver enzyme that metabolizes about half of all prescription drugs).

Reported side effects

In RCTs and case reports on chamomile, the most frequently documented side effect is mild sedation and drowsiness, which in the context of sleep is partly the intended effect. Gastrointestinal discomfort has been reported at higher doses. Allergic reactions are rare but real: chamomile belongs to the daisy family (Asteraceae), and people who are hypersensitive to mugwort, marigold or other members of the daisy family are at risk of cross-reactivity. Allergic contact dermatitis has been documented with topical use of chamomile and, rarely, with oral preparations. A historical safety review of herbal sedatives, including chamomile, in cancer care found an overall mild side effect profile. More recent safety data from anxiety trials with oral chamomile fit this assessment. The documented studies and case reports do not, however, establish general safety for every population and every dose. Source Source

Possible interactions with CYP3A4 and sedating agents

• CYP3A4 substrates (statins, immunosuppressants, many psychiatric drugs), moderate. Apigenin inhibits CYP3A4 in vitro; this is clinically relevant when it is combined with CYP3A4 substrates that have a narrow therapeutic index. Source

• Benzodiazepines and other CNS depressants, moderate. Pharmacologically, additional sedation is expected through partial benzodiazepine agonism. Source

• Alcohol, moderate. Increased CNS depression. Combining daily evening alcohol with apigenin taken for sleep adds to the sedative load.

• Sedating antihistamines and opioids, mild to moderate. Additional sedation. The source article does not classify the combination as contraindicated but lists it as a relevant point when reviewing multiple medications.

For CYP3A4 specifically, the clinical pharmacology evidence for apigenin is thinner than for grapefruit juice. These interactions are better described as pointers to theoretical mechanisms than as confirmed clinical case series. If you take several medications, have a doctor check before adding apigenin what the CYP3A4 inhibition by flavonoids seen in vitro, and their CYP3A4 interactions, could mean for your existing treatment. Source

Pregnancy, breastfeeding and organ function

Apigenin supplementation is generally avoided during pregnancy and breastfeeding because there are no controlled human safety data at supplement doses. Chamomile tea consumed in normal culinary amounts has a longer history of use in these groups, but that history does not extend to isolated apigenin capsules of 50 to 100 mg. With impaired liver function, caution is warranted given the CYP3A4 modulation signal. There are no specific data on apigenin in kidney impairment. In children, chamomile preparations have a longer pediatric tradition in folk medicine, but there are no controlled data on isolated apigenin in children. People with a known Asteraceae allergy should avoid chamomile products entirely.

Who should avoid apigenin?

For several groups, the balance of benefit and risk for apigenin supplements is unfavorable. The following list is not exhaustive:

• Pregnant or breastfeeding people, no controlled human safety data at supplement doses.

• Asteraceae allergy (allergy to ragweed, marigold, daisies, chamomile), risk of an allergic reaction.

• Concurrent use of benzodiazepines, opioids or daily alcohol, additive CNS depression.

• Concurrent use of CYP3A4 substrates with a narrow therapeutic index (certain statins, immunosuppressants, antiarrhythmics), risk of interactions.

• Active suicidal thoughts, severe insomnia or treatment-resistant anxiety, medical evaluation required.

• Children, supplement doses have not been adequately studied in children.

If any of these apply, get medical advice before taking it. Your full medication list and any existing lab results are relevant to that conversation.

How changes in sleep and anxiety can be tracked

Sleep quality is not a blood biomarker. To capture possible changes, the source article names the validated Pittsburgh Sleep Quality Index (PSQI) questionnaire, actigraphy and blood markers. The blood markers are meant to reflect biological processes that apigenin might influence through its GABAergic and anxiety-relieving mechanisms.

• AM cortisol: meant to reflect strain on the HPA axis. Apigenin’s anxiety-relieving mechanism may point to a small downward shift in elevated baseline levels over 4 to 8 weeks, if the GABAergic mechanism takes effect. Persistently elevated AM cortisol after 8 weeks can be informative in its own right.

• hs-CRP: a marker of systemic inflammation; apigenin’s anti-inflammatory and anxiety-relieving mechanisms overlap, and persistently elevated hs-CRP signals a burden that a flavonoid supplement is unlikely to resolve on its own.

• Sleep quality and sleep duration (PSQI, actigraphy or a wearable): not a blood test, but the primary endpoints of the chamomile RCTs. The source article calls for at least one measurement on day 0 and day 56 with the same instrument so that any change can be interpreted.

• Estradiol: for postmenopausal and postpartum women, the groups for which the source article describes the strongest evidence of chamomile’s effect on sleep. Estradiol provides hormonal context for changes in sleep architecture; it is not a direct marker of apigenin’s effect.

• (Optional) NAD+ panel: exploratory only. The CD38/NAD+ longevity mechanism is preclinical, so in this context an NAD+ panel is better suited to generating research hypotheses than to serving as a validated marker of response to apigenin.

Measuring AM cortisol, hs-CRP and a baseline for sleep quality before starting apigenin or a standardized chamomile extract provides the objective reference points that make any later change interpretable. Without a baseline, a perceived improvement cannot be told apart from regression to the mean or a placebo effect. The source article presents tracking these markers over 8 weeks, the minimum duration used in most chamomile RCTs, as the yardstick for a meaningful assessment.

When a medical evaluation matters more

If the reason you are reaching for an apigenin supplement is chronic insomnia, defined as sleep problems on more than three nights a week for more than three months, an evaluation by your primary care doctor or a sleep medicine specialist is warranted. Cognitive behavioral therapy for insomnia (CBT-I) has much stronger evidence for chronic insomnia than any flavonoid and is the first-line recommendation in current clinical guidelines. Persistent anxiety that interferes with daily functioning should be evaluated by a doctor or psychiatrist. Chamomile’s anxiety-relieving effect applies to mild to moderate anxiety, not to treatment-resistant or severe symptoms. Source

Frequently asked questions

What is apigenin?

Apigenin is a flavone (a subclass of flavonoids) that is especially concentrated in chamomile but also occurs in parsley, celery and other plants. It binds to the GABA-A receptor at a site it shares with some sedatives, with much weaker activity.

Does apigenin actually help with sleep?

There are only limited human data on a sleep-promoting effect of isolated apigenin. Small improvements in sleep quality over 2 to 4 weeks have been seen in older adults in studies of chamomile (the primary natural source of apigenin), but not in RCTs of isolated apigenin. Data on when to take isolated apigenin are also sparse, which makes it hard to pin down the best dose or timing for isolated apigenin specifically. Source Source

What apigenin dose has been used in studies?

Studies of standardized chamomile extract used 220 to 1,500 mg/day over 2 to 8 weeks. Isolated apigenin supplement doses in the range of 25 to 100 mg are typical of available products, although data from human studies matching these doses are still limited. Source Source

What are the side effects of apigenin?

The side effects reported most often in studies and case reports are mild sedation, drowsiness and gastrointestinal discomfort. Rare allergic reactions have been documented in people sensitive to plants of the daisy family (Asteraceae), such as mugwort, marigold and daisies.

Are apigenin supplements FDA-approved?

According to the source article, as of May 2026 apigenin is sold in the United States as a dietary supplement under DSHEA, but it is not FDA-approved and the FDA has not reviewed it for efficacy. Standardized chamomile preparations are also sold as dietary supplements. As of the last update, apigenin is not on the WADA Prohibited List.

Is apigenin the same as chamomile?

Apigenin is not the same as chamomile, although apigenin is the main flavonoid in chamomile. Besides apigenin, chamomile contains other bioactive compounds and therefore a broader mix of active ingredients, for which there is more experience of use in humans. Isolated apigenin captures one mechanism, while whole chamomile offers a more complex therapeutic profile. Source

Does apigenin interact with medications?

Apigenin inhibits CYP3A4, which affects the metabolism of statins, immunosuppressants and many psychotropic medications. If you take medications like these, discuss adding apigenin with your prescriber first. Combined with benzodiazepines, alcohol, opioids or other CNS depressants, it can cause additional sedation. Because controlled safety data are lacking, apigenin is generally avoided during pregnancy and breastfeeding. Source

Which blood tests should I have before trying apigenin?

For use with sleep problems or anxiety, the source article lists baseline measurements of AM cortisol and hs-CRP, along with tracking sleep quality (PSQI or actigraphy). For postmenopausal or postpartum women, it also describes estradiol measurements as informative. NAD+ tests remain exploratory; they are not validated proof that apigenin is working.

Sources

• Viola H, Wasowski C, Levi de Stein M, Wolfman C, Silveira R, Dajas F, Medina JH, Paladini AC (1995). Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects. Planta Medica, 61(3), 213–216. https://doi.org/10.1055/s-2006-958058 Source

• De Oliveira DD, Prinholato da Silva C, Falconi-Sobrinho LL, Oliveira Beleboni R (2024). Long‑term effects of vitexin against development of pentylenetetrazole‑induced kindling in rats. Acta neurobiologiae experimentalis, 84(3), 266-274. https://doi.org/10.55782/ane-2024-2575 Source

• Sepp J, Koshovyi O, Jakstas V, Žvikas V, Botsula I, Kireyev I, Tsemenko K, Kukhtenko O, Kogermann K, Heinämäki J, Raal A (2024). Phytochemical, Technological, and Pharmacological Study on the Galenic Dry Extracts Prepared from German Chamomile (. Plants (Basel, Switzerland), 13(3). https://doi.org/10.3390/plants13030350 Source

• Wong TY, Tsai MS, Hsu LC, Lin SW, Liang PH (2018). Traversal of the Blood-Brain Barrier by Cleavable l-Lysine Conjugates of Apigenin. Journal of agricultural and food chemistry, 66(30), 8124-8131. https://doi.org/10.1021/acs.jafc.8b01187 Source

• Kramer DJ, Johnson AA (2024). Apigenin: a natural molecule at the intersection of sleep and aging. Frontiers in nutrition, 11, 1359176. https://doi.org/10.3389/fnut.2024.1359176 Source

• Sánchez M, González-Burgos E, Iglesias I, Lozano R, Gómez-Serranillos MP (2020). Current uses and knowledge of medicinal plants in the Autonomous Community of Madrid (Spain): a descriptive cross-sectional study. BMC complementary medicine and therapies, 20(1), 306. https://doi.org/10.1186/s12906-020-03089-x Source

• Block KI, Gyllenhaal C, Mead MN (2004). Safety and efficacy of herbal sedatives in cancer care. Integrative cancer therapies, 3(2), 128-48. https://doi.org/10.1177/1534735404265003 Source

• Saadatmand S, Zohroudi F, Tangestani H (2024). The Effect of Oral Chamomile on Anxiety: A Systematic Review of Clinical Trials. Clinical nutrition research, 13(2), 139-147. https://doi.org/10.7762/cnr.2024.13.2.139 Source

• Socała K, Kowalczuk-Vasilev E, Komar M, Szalak R, Wyska E, Wlaź P (2025). Effect of apigenin on seizure susceptibility, parvalbumin immunoreactivity, and GABA. European journal of pharmacology, 996, 177548. https://doi.org/10.1016/j.ejphar.2025.177548 Source

• Orhan IE (2021). A Review Focused on Molecular Mechanisms of Anxiolytic Effect of Valerina officinalis L. in Connection with Its Phytochemistry through in vitro/in vivo Studies. Current pharmaceutical design, 27(28), 3084-3090. https://doi.org/10.2174/1381612827666210119105254 Source

• Escande C, Nin V, Price NL, Capellini V, Gomes AP, Barbosa MT, O’Neil L, White TA, Sinclair DA, Chini EN (2013). Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes, 62(4), 1084-93. https://doi.org/10.2337/db12-1139 Source

• Alabarse PG, Oliveira P, Qin H, Yan T, Migaud M, Terkeltaub R, Liu-Bryan R (2024). The NADase CD38 is a central regulator in gouty inflammation and a novel druggable therapeutic target. Inflammation research : official journal of the European Histamine Research Society … [et al.], 73(5), 739-751. https://doi.org/10.1007/s00011-024-01863-y Source

• Roboon J, Hattori T, Ishii H, Takarada-Iemata M, Nguyen DT, Heer CD, O’Meally D, Brenner C, Yamamoto Y, Okamoto H, Higashida H, Hori O (2021). Inhibition of CD38 and supplementation of nicotinamide riboside ameliorate lipopolysaccharide-induced microglial and astrocytic neuroinflammation by increasing NAD. Journal of neurochemistry, 158(2), 311-327. https://doi.org/10.1111/jnc.15367 Source

• Zick SM, Wright BD, Sen A, Arnedt JT (2011). Preliminary examination of the efficacy and safety of a standardized chamomile extract for chronic primary insomnia: a randomized placebo-controlled pilot study. BMC complementary and alternative medicine, 11, 78. https://doi.org/10.1186/1472-6882-11-78 Source

• Abdullahzadeh M, Matourypour P, Naji SA (2017). Investigation effect of oral chamomilla on sleep quality in elderly people in Isfahan: A randomized control trial. Journal of education and health promotion, 6, 53. https://doi.org/10.4103/jehp.jehp_109_15 Source

• de Castro JM, da Silva Melo A, Silveira BL, Martins IAS, Marçal MM, Bosco TD, Keingeski MB, Oliveira ECL, Alvares-da-Silva MR, Türck P, Araujo ASDR, Ayres LR, Kowalewski LS, Russo MKB, Krause M, Stein DJ, Torres ILS (2025). Oral apigenin prevents obesity-related muscular atrophy, but not obesity itself, in middle-aged rats fed a high-calorie diet. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 189, 118342. https://doi.org/10.1016/j.biopha.2025.118342 Source

• Bayliak MM, Dmytriv TR, Melnychuk AV, Strilets NV, Storey KB, Lushchak VI (2021). Chamomile as a potential remedy for obesity and metabolic syndrome. EXCLI journal, 20, 1261-1286. https://doi.org/10.17179/excli2021-4013 Source

• Li Y, Ning J, Wang Y, Wang C, Sun C, Huo X, Yu Z, Feng L, Zhang B, Tian X, Ma X (2018). Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicology letters, 294, 27-36. https://doi.org/10.1016/j.toxlet.2018.05.008 Source